Trajan (ASX:TRJ): Earnings Recovery, AI & the Future of Healthcare

Can Trajan (ASX:TRJ) turn its improving earnings and cash generation into sustained growth? In this Homodeus Research webinar, co-founder, CEO and Managing Director Stephen Tomisich joins Wei Sim to discuss Trajan Group Holdings’ FY27 earnings recovery, debt reduction and opportunities to improve margins across its global analytical and life sciences business. Stephen explains how manufacturing consolidation, automation and better utilisation of Trajan’s global footprint could support profitability. The discussion also covers components and consumables growth, laboratory robotics, AI, mass spectrometry software and blood microsampling for therapeutic drug monitoring. Investor questions explore cash conversion, customer concentration, competitive advantages, acquisition priorities, capital allocation and Trajan’s longer-term role in personalised, preventative healthcare. TIMESTAMPS 00:00 Introduction 01:31 Stephen Tomisich: Presentation Overview 01:55 Trajan’s Business & Healthcare Strategy 03:34 Components, Consumables & Laboratory Robotics 04:14 Acquisition Strategy & Integration 07:12 Global Manufacturing Footprint & Spare Capacity 08:34 Long-Term Margin Ambitions 09:02 Products, Markets & Global Customers 10:03 FY26 Results & Foreign Exchange Impact 12:41 Manufacturing Consolidation & Cost Savings 14:04 FY27 Q1 Trading Update & Earnings Recovery 14:57 Working Capital & Debt Reduction 16:22 Components & Consumables Growth 16:53 FY27 Outlook & AGM Guidance Update 17:53 Investor Q&A: Drivers of Earnings Improvement 20:16 Organic Growth Outlook 21:07 Acquisition Integration & Founder Retention 22:08 Cash Conversion, Debt & Banking Covenants 23:12 Spare Capacity & Site Consolidation 25:01 Customer Concentration & Global Relationships 27:49 Competition & Analytical Precision 30:30 AI, Laboratory Software & Drug Discovery 32:52 Growth Across Pharma, Clinical & Other Markets 33:28 Blood Microsampling & Therapeutic Drug Monitoring 34:18 Food Industry Headwinds & Capital Equipment 35:14 Acquisition Pipeline & Capital Raising 36:01 Debt Targets & Balance Sheet Management 36:49 Property Ownership & Potential Asset Sales 37:36 Further Consolidation & Margin Opportunities 39:38 Trajan’s Competitive Advantages 42:13 Equipment, Services & Recurring Revenue 44:11 Manufacturing IP & Robotics 46:15 Three-to-Five-Year Strategy & New Products 48:49 Closing Remarks ABOUT HOMODEUS RESEARCH Homodeus Research hosts in-depth conversations with ASX-listed companies, fund managers and industry experts to help investors better understand businesses, industries and long-term opportunities. Subscribe for more executive interviews and investor webinars. DISCLAIMER This webinar is provided for educational purposes only and should not be considered financial advice. Always conduct your own research and seek advice from a licensed financial adviser before making investment decisions. #Trajan #ASXTRJ #LifeSciences